Ligand Pharmaceuticals Inc (LGNZZ) — SEC Filings
Ligand Pharmaceuticals Inc (LGNZZ) — 46 SEC filings. Latest: 8-K (Dec 18, 2025). Includes 26 8-K, 6 10-Q, 6 SC 13G/A.
View Ligand Pharmaceuticals Inc on SEC EDGAR
Overview
Ligand Pharmaceuticals Inc (LGNZZ) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 18, 2025: Ligand Pharmaceuticals Inc. announced on December 18, 2025, a current report filing (8-K) with the SEC. The filing pertains to Regulation FD Disclosure and was submitted from their principal executive offices in Jupiter, Florida.
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 4 bullish, 1 bearish, 41 neutral. The dominant filing sentiment for Ligand Pharmaceuticals Inc is neutral.
Filing Type Overview
Ligand Pharmaceuticals Inc (LGNZZ) has filed 26 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 2 DEFA14A, 2 SC 13G with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of LGNZZ's 38 recent filings, 1 were flagged as high-risk, 16 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $115.46M |
| Net Income | $117.27M |
| EPS | $6.07 |
| Debt-to-Equity | 0.54 |
| Cash Position | $139.38M |
| Operating Margin | N/A |
| Total Assets | $1,476.77M |
| Total Debt | $445.49M |
Key Executives
- Todd Davis
- Todd C. Davis
- Tavo Espinoza
- Andrew Reardon
- Matthew Korenberg
- John L. Higgins
- Dr. Jason L. Adlakha
- Dr. John P. McLellan
- Todd Simon
- Michael H. Riordan
Industry Context
Ligand Pharmaceuticals operates in the biopharmaceutical sector, focusing on enabling scientific advancement through financing and licensing. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success is often driven by strategic partnerships and the ability to identify and support promising drug candidates.
Top Tags
material-agreement (6) · pharmaceuticals (5) · 10-Q (4) · institutional-ownership (4) · disclosure (3) · sec-filing (3) · financial-reporting (3) · corporate-governance (3) · quarterly-report (3) · 8-k (3)
Executive Compensation
From the most recent DEF 14A filing (Apr 25, 2024):
- Todd C. Davis — Member
- John L. Higgins — Member
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $117.27M | Increased from a net loss of $7.17M in Q3 2024 |
| Total Revenues and Other Income | $115.46M | Increased from $51.81M in Q3 2024 |
| Royalties | $46.59M | Increased from $31.71M in Q3 2024, a 51.2% rise |
| Contract Revenue and Other Income | $58.20M | Increased from $13.85M in Q3 2024 |
| Gain from change in fair value of equity-method investments and other investments | $75.89M | Compared to a loss of $3.03M in Q3 2024 |
| Research and Development Expenses (Q3 2025) | $21.02M | Increased from $5.68M in Q3 2024 |
| Research and Development Expenses (9 months 2025) | $77.67M | Increased from $17.00M in 9 months 2024 |
| Cash and Cash Equivalents | $139.38M | As of September 30, 2025, up from $72.31M at December 31, 2024 |
| Net cash provided by financing activities | $419.89M | For the nine months ended September 30, 2025 |
| Gross proceeds from issuance of 2030 Convertible Senior Notes | $460.00M | For the nine months ended September 30, 2025 |
| Total Revenue Q2 2025 | $15.0M | Down 40% from $25.0M in Q2 2024 |
| Total Revenue H1 2025 | $30.0M | Down 40% from $50.0M in H1 2024 |
| Royalty Revenue Q2 2025 | $10.0M | Decreased by $5.0M from Q2 2024 |
| Captisol Sales Q2 2025 | $3.0M | Decreased by 62.5% from $8.0M in Q2 2024 |
| Revenue Decline | 40% | Percentage decrease in total revenue for Q2 and H1 2025 year-over-year |
Forward-Looking Statements
- {"claim":"Vanguard will maintain a significant, passive stake in Ligand Pharmaceuticals for the foreseeable future.","entity":"The Vanguard Group","targetDate":"December 29, 2024","confidence":"high"}
- {"claim":"Other institutional investors may increase their positions in Ligand Pharmaceuticals Inc. following Goldman Sachs's disclosure.","entity":"Ligand Pharmaceuticals Inc.","targetDate":"Q2 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Ligand Pharmaceuticals Inc (LGNZZ)?
Ligand Pharmaceuticals Inc has 46 recent SEC filings from Jan 2024 to Dec 2025, including 26 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LGNZZ filings?
Across 46 filings, the sentiment breakdown is: 4 bullish, 1 bearish, 41 neutral. The dominant sentiment is neutral.
Where can I find Ligand Pharmaceuticals Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Ligand Pharmaceuticals Inc (LGNZZ) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Ligand Pharmaceuticals Inc?
Key financial highlights from Ligand Pharmaceuticals Inc's most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LGNZZ?
The investment thesis for LGNZZ includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Ligand Pharmaceuticals Inc?
Key executives identified across Ligand Pharmaceuticals Inc's filings include Todd Davis, Todd C. Davis, Tavo Espinoza, Andrew Reardon, Matthew Korenberg and 5 others.
What are the main risk factors for Ligand Pharmaceuticals Inc stock?
Of LGNZZ's 38 assessed filings, 1 were flagged high-risk, 16 medium-risk, and 21 low-risk.
What are recent predictions and forward guidance from Ligand Pharmaceuticals Inc?
Recent forward-looking statements from Ligand Pharmaceuticals Inc include guidance on {"claim":"Vanguard will maintain a significant, passive stake in Ligand Pharmaceuticals for the foreseeable future.","en and 1 other predictions.